Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Publication year range
1.
Eur J Gastroenterol Hepatol ; 20(1): 15-21, 2008 Jan.
Article in English | MEDLINE | ID: mdl-18090984

ABSTRACT

AIM: Endoscopic sphincterotomy is an efficient means of treating sphincter of Oddi dysfunction (SOD), but it is associated with a morbidity rate of 20%. The aim of this study was to assess how frequently endoscopic sphincterotomy was performed to treat SOD in a group of patients with a 1-year history of medical management. METHODS: A total of 59 patients, who had been cholecystectomized 9.3 years previously on average, were included in this study and they all underwent biliary scintigraphy. Medical treatment was prescribed for 1 year. Endoscopic sphincterotomy was proposed for patients whose medical treatment had been unsuccessful. RESULTS: Eleven patients were rated group 1 on the Milwaukee classification scale, 34 group 2 and 14 group 3. The hile-duodenum transit time (HDTT) was lengthened in 32 patients. The medical treatment was efficient or fairly efficient in 45% of the group 1 patients, 67% of the group 2 patients, and 71.4% of the group 3 patients (P=0.29). Only 14 patients out of the 21 whose medical treatment was unsuccessful agreed to undergo endoscopic sphincterotomy. HDTT was lengthened in 11 of the 14 patients undergoing endoscopic sphincterotomy and in 21 of the 45 non-endoscopic sphincterotomy patients (P=0.03). Twelve of the 14 patients who underwent endoscopic sphincterotomy were cured. CONCLUSION: In this prospective series of patients with a 1-year history of medical management, only 23% of the patients with suspected SOD underwent endoscopic sphincterotomy although 54% had an abnormally long HDTT.


Subject(s)
Sphincter of Oddi Dysfunction/surgery , Sphincterotomy, Endoscopic/methods , Adult , Aged , Cholecystectomy/adverse effects , Female , Follow-Up Studies , Gastrointestinal Transit/physiology , Humans , Male , Middle Aged , Pain, Postoperative/etiology , Prospective Studies , Sphincter of Oddi Dysfunction/diagnosis , Sphincter of Oddi Dysfunction/pathology , Sphincterotomy, Endoscopic/statistics & numerical data , Treatment Outcome
2.
Presse Med ; 34(9): 651-4, 2005 May 14.
Article in French | MEDLINE | ID: mdl-15988340

ABSTRACT

INTRODUCTION: Hepatitis E virus is endemic in developing countries where it is especially lethal among pregnant women. As the circulation of goods and people grows between these countries and the industrialized nations, this virus is emerging as a cause of imported acute hepatitis in the latter, where authentic autochthonous cases also exist. OBSERVATIONS: We report two cases observed in Marseille, in men aged 27 and 81 years; no mode of contamination was detected, and both outcomes were positive. DISCUSSION: This virus is circulating in non-endemic areas (as shown by its seroprevalence, which ranges from 0.4 to 2.6%, its identification in urban sewage, and the autochthonous cases reported). This dissemination, combined with its high mortality rate, even outside pregnancy (up to 12%), show the need for systematic consideration of and an early search for the often-fleeting presence of the virus and of IgM and IgG type serum antibodies in plasma and (when necessary) feces in cases of acute hepatitis, because of their often transient nature. Prophylaxis is based on improving water hygiene and is thus more difficult in industrialized countries where the level of hygiene is already high, especially when no risk factors can be identified in the autochthonous cases. Recombinant vaccines are under development.


Subject(s)
Hepatitis E/epidemiology , Adult , Aged , Aged, 80 and over , Antibodies, Viral/blood , Communicable Diseases, Emerging/epidemiology , Early Diagnosis , Feces/virology , France/epidemiology , Hepatitis E/virology , Hepatitis E virus/immunology , Hepatitis E virus/isolation & purification , Humans , Immunoglobulin G/blood , Immunoglobulin M/blood , Liver Function Tests , Male , RNA, Viral/blood , Viremia/diagnosis
3.
Presse Med ; 34(10): 728-30, 2005 Jun 04.
Article in French | MEDLINE | ID: mdl-16026127

ABSTRACT

INTRODUCTION: Chronic viral C hepatitis can be cured by shorter treatment than recommended. It is illustrated by our two case reports. CASES: We report two cases of chronic viral C hepatitis cured by short therapy with interferon standard alone in one case and the combination of pegylated-interferon and ribavirin in the second case. Genotype was undetermined for one patient and 3a for the other. DISCUSSION: Excepted genotyping and early testing of viral load decrease during treatment (12th week), we lack early predictive factors of sustained response that could help avoid prolonged, poorly tolerated therapy in future non-responders. These observations show that the treatment duration of chronic viral C hepatitis can be shortened in selected patients, who should be identified as soon as possible after the beginning of the treatment.


Subject(s)
Antiviral Agents/therapeutic use , Hepatitis C, Chronic/drug therapy , Interferon-alpha/therapeutic use , Polyethylene Glycols/therapeutic use , Ribavirin/therapeutic use , Adult , Drug Administration Schedule , Drug Therapy, Combination , Humans , Interferon alpha-2 , Male , Recombinant Proteins
SELECTION OF CITATIONS
SEARCH DETAIL
...